Deksanabinol

Deksanabinol
IUPAC ime
	(6aS,10aS)-9-(Hidroksimetil)- 6,6-dimetil- 3-(2-metiloktan-2-il)- 6a,7,10,10a-tetrahidrobenzo [c]hromen-1-ol
Identifikatori
CAS broj	112924-45-5
ATC kod	none
PubChem	CID 107778
ChemSpider	96934
UNII	R6VT8U5372
Hemijski podaci
Formula	C25H38O3
Molarna masa	386,567 g/mol
	SMILES Oc2cc(cc1OC([C@H]3C/C=C(\C[C@@H]3c12)CO)(C)C)C(C)(C)CCCCCC; ;
	InChI InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1 ; Key:SSQJFGMEZBFMNV-PMACEKPBSA-N ;

Deksanabinol (HU-211, ETS2101^[1]) je sintetički kanabinoidni derivat koji je „neprirodni“ enantiomer potentnog kanabinoidnog agonista HU-210.^[2] Za razliku od kanabinoidnih derivata, HU-211 ne deluje kao agonist kanabinoidnog receptora, nego kao NMDA antagonist.^[3] On stoga ne proizvodi kanabisu slične efekte, ali je antikonvulsant i neuroprotektivan, te nalazi široku primenu u naučnim istraživanjima. On se takođe izučava za moguću primenu u tretmanu povrede glave, moždanog udara i kancera.^[4]^[5]^[6] Klinička istraživanja su pokazala da je bezbedan.^[7]^[8]

Reference

^ e-therapeutics Clinical Development Pipeline Архивирано на сајту Wayback Machine (26. јануар 2013)
^ Pop E (2000). „Nonpsychotropic synthetic cannabinoids”. Current Pharmaceutical Design. 6 (13): 1347—60. PMID 10903397. doi:10.2174/1381612003399446.
^ Feigenbaum JJ; et al. (1989). „Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker”. Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584—7. PMC 298542  . PMID 2556719. doi:10.1073/pnas.86.23.9584.
^ Biegon A; Joseph AB (1995). „Development of HU-211 as a neuroprotectant for ischemic brain damage”. Neurological Research. 17 (4): 275—80. PMID 7477742.
^ Darlington CL (2003). „Dexanabinol: a novel cannabinoid with neuroprotective properties”. IDrugs : the Investigational Drugs Journal. 6 (10): 976—9. PMID 14534855.
^ Vink R; Nimmo AJ (2009). „Multifunctional drugs for head injury”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 6 (1): 28—42. PMID 19110197. doi:10.1016/j.nurt.2008.10.036.
^ Maas AI; et al. (2006). „Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial”. Lancet Neurol. 5 (1): 38—45. PMID 16361021. doi:10.1016/S1474-4422(05)70253-2.
^ University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment Архивирано на сајту Wayback Machine (1. август 2013)". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[e-th-1] -therapeutics Clinical Development Pipeline Архивирано на сајту Wayback Machine (26. јануар 2013)

[pmid10903397-2] Pop E (2000). „Nonpsychotropic synthetic cannabinoids”. Current Pharmaceutical Design. 6 (13): 1347—60. PMID 10903397. doi:10.2174/1381612003399446.

[pmid2556719-3] Feigenbaum JJ; et al. (1989). „Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker”. Proceedings of the National Academy of Sciences of the United States of America. 86 (23): 9584—7. PMC 298542  . PMID 2556719. doi:10.1073/pnas.86.23.9584.

[pmid7477742-4] Biegon A; Joseph AB (1995). „Development of HU-211 as a neuroprotectant for ischemic brain damage”. Neurological Research. 17 (4): 275—80. PMID 7477742.

[pmid14534855-5] Darlington CL (2003). „Dexanabinol: a novel cannabinoid with neuroprotective properties”. IDrugs : the Investigational Drugs Journal. 6 (10): 976—9. PMID 14534855.

[pmid19110197-6] Vink R; Nimmo AJ (2009). „Multifunctional drugs for head injury”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 6 (1): 28—42. PMID 19110197. doi:10.1016/j.nurt.2008.10.036.

[pmid16361021-7] Maas AI; et al. (2006). „Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial”. Lancet Neurol. 5 (1): 38—45. PMID 16361021. doi:10.1016/S1474-4422(05)70253-2.

[8] University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment Архивирано на сајту Wayback Machine (1. август 2013)". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]